Molecular Therapy, 2009 · DOI: 10.1038/mt.2009.168 · Published: July 21, 2009
The study investigates whether blocking the RhoA-ROCK signal pathway, known to inhibit axon regeneration after CNS injury, can promote axon outgrowth and functional recovery. This was achieved by neuron-specific expression of a dominant negative mutant of ROCK (DNROCK) using lentiviral vectors. In vitro experiments showed that DNROCK-expressing neurons had a greater chance of generating neurites and longer neurites compared to control neurons when seeded on myelin proteins, which are known inhibitors of axon growth. In vivo experiments involved injecting lentiviruses into the red nucleus of adult rats, followed by transection of the rubrospinal tract (RST). The DNROCK group exhibited better functional recovery in both hindlimbs and forelimbs compared to the control group, with more RST axons growing to the spinal cord caudal to the lesion.
The RhoA-ROCK pathway is validated as a therapeutic target for promoting axonal regeneration after CNS injury.
Lentiviral delivery of DNROCK shows promise as a gene therapy approach to enhance axon outgrowth and functional recovery.
Combining DNROCK expression with other strategies, such as modifying the glial scar or co-expressing growth-promoting molecules, may further enhance CNS axon regeneration.